Belsomra (suvorexant) is Merck’s dual orexin receptor antagonist for insomnia, approved in 2014 and sold as a Schedule IV controlled substance in four strengths. It was the first drug in its class, and more than a decade later it is still brand-only, which is the single fact that sets the price.
Everything below was pulled fresh on September 3, 2026 from CMS pricing files, Merck’s own statutory price disclosure, and Merck’s coupon activation site. This is a money and paperwork guide, not medical advice, and nothing here speaks to whether the drug is right for you.
What Does Belsomra Cost Without Insurance?
Belsomra is dispensed as a unit-of-use carton of 30 tablets, so a carton is one month of nightly dosing and is the unit nearly every price is quoted in. The unusual thing about this drug is that all four strengths cost the same. Merck’s list price row comes from the wholesale acquisition cost it discloses to Colorado prescribers under state law, with pricing data extracted November 19, 2025. The acquisition-cost row is CMS’s National Average Drug Acquisition Cost survey, which measures what retail pharmacies actually pay wholesalers, effective August 19, 2026.
| Price point | Low | Average / typical | High |
|---|---|---|---|
| 30 tablets, published cash price (any strength) | $473.83 | $473.83 | $473.83 |
| Merck published list price (WAC), 30-tablet carton | $477.00 | $477.00 | $477.00 |
| Pharmacy acquisition cost (NADAC), 30 tablets | $455.96 | $456.22 | $456.41 |
| Per tablet, cash | $15.19 | $15.79 | $15.90 |
| Medicare Part D average per fill, 2024 | $476.16 | $476.16 | $476.16 |
| Merck savings coupon (private insurance only) | $30 | $30 | $30 |
| Merck Patient Assistance Program (approved applicants) | $0 | $0 | $0 |
| Generic zolpidem 10 mg, 30 tablets (NADAC acquisition) | $1.17 | $1.17 | $1.17 |
The honest cross-source range for 30 tablets is about $456 to $477, and the three sources agree unusually closely. Merck’s disclosed WAC is $477.00, the published cash price on Drugs.com read September 3, 2026 is $473.83, and NADAC’s per-tablet figure of roughly $15.20 works out to about $456 for a carton. When three independent measurements land inside 5% of each other, the number is real.
Treat the low end as a floor rather than a quote. NADAC is what the pharmacy paid, not what it charges you, and an individual store adds its own markup and dispensing fee on top. Cash quotes for brand drugs also move between pharmacies on the same day, so price the script at three stores before you fill it.
The Medicare number is a useful sanity check
CMS’s Medicare Part D Spending by Drug dataset, data year 2024, shows Belsomra at an average of $14.51 per dosage unit and $476.16 per claim across 315,401 claims and 77,098 beneficiaries, with total Part D spending of $150.2 million. Average spending per beneficiary that year was $1,947.91. Those figures are gross of rebates, but they confirm that a routine fill is a mid-three-figure transaction and that a full year on the drug is roughly $2,000.
What Drives the Price
No generic exists yet, and tentative approval is not a launch. FDA’s Drugs@FDA database shows Hetero Labs holds ANDA 219386 for suvorexant tablets at 5, 10, 15 and 20 mg. Every one of those products carries a marketing status of “None (Tentative Approval)” dated December 22, 2025. That means FDA has cleared the science but the copy cannot be sold until patent barriers clear.
The patent wall runs to 2033. FDA’s Orange Book lists four unexpired patents on Belsomra. Patent 7,951,797 expires November 20, 2029, and three drug-product patents (10,098,892, 11,980,623 and 12,599,610) all expire May 29, 2033. The most recent of the three was submitted to FDA on June 17, 2026, which is not the behavior of a company expecting generic competition soon.
Flat pricing across strengths. Merck charges the same $477.00 WAC whether the carton holds 5 mg or 20 mg tablets, and NADAC prices the four strengths within a penny of one another. On most drugs a dose reduction saves money. Here it does not, so there is no cost argument for asking your prescriber about a lower strength.
It is a controlled substance. Belsomra is Schedule IV, which caps refills and rules out the 90-day fills that usually cut per-unit cost on chronic medications. You are buying 30 tablets at a time, roughly twelve times a year, at full price each time.
Merck sees no generic competitor in the class. Colorado law requires manufacturers to list generic drugs in the same therapeutic class as the marketed drug. On the Belsomra disclosure, using data extracted November 19, 2025, that list reads “N/A.” Merck is telling the state there is nothing generic that competes with it directly.
Cash Price vs. Insurance
For a commercially insured patient, insurance almost always wins here, because Merck’s coupon can bring a copay down to $30. The catch is that the coupon covers only your out-of-pocket cost above $30, up to a maximum of $150 per fill, once every 30 days, with an expiration date of December 31, 2026. On a $477 prescription, $150 of help still leaves a large bill if your plan pays nothing.
The eligibility line is the one that matters for our reader. Merck’s own coupon activation site states that the patient must have private insurance and that the offer is not valid for uninsured patients, or for anyone covered by Medicaid, Medicare, Medicare Part D or Advantage, TRICARE, CHAMPUS or any other government program. If you are paying cash, the coupon is not a lever you have.
There is one gap worth knowing. The terms do extend to patients who are privately insured but whose plan does not cover Belsomra, in which case they “make full cash payment” and the coupon still applies. So a commercial plan with a Belsomra exclusion is better than no plan at all, purely on this drug.
Prior authorization is the usual friction point even with coverage. Many plans require you to try a cheap generic sedative first. If your plan denies the drug outright, you are functionally a cash payer, and everything in the next section applies to you.
How to Pay Less
Apply to the Merck Patient Assistance Program. This is the only route to $0 for an uninsured patient. Merck’s program page describes it as providing certain medicines free of charge for up to a year to eligible individuals, primarily the uninsured, who could not otherwise afford them, and says people who miss the insurance criteria may still qualify by attesting to special circumstances of financial and medical hardship. Merck does not publish a numeric income cutoff on its site; it directs applicants to call 800-727-5400 for the current financial criteria. Belsomra is a covered product. The enrollment form is mailed, both you and your prescriber sign it, and one approval can cover up to a 3-month supply plus three refills.
Price a free discount card at three pharmacies before you fill. Brand cash quotes on a Schedule IV drug vary by store, and the gap between the cheapest and most expensive pharmacy in a metro area is often larger than any card discount. Compare the two big free cards in our guide to GoodRx vs. SingleCare, then call three stores with the exact strength and quantity written on your script.
Ask your prescriber to price the generic sleep drugs honestly. The gap is not subtle. Per CMS NADAC effective August 19, 2026, 30 tablets of zolpidem 10 mg cost a pharmacy about $1.17, trazodone 50 mg about $0.94, temazepam 15 mg about $2.37, eszopiclone 3 mg about $2.57, ramelteon 8 mg about $19.72, and low-dose doxepin 6 mg about $43.34. That is not a clinical recommendation and orexin antagonists exist for good reasons, but if cost is the binding constraint the conversation is worth having. See our trazodone cash price guide for what pharmacies actually charge on the cheapest of them.
Check a community health center first. Federally qualified health centers charge on a sliding scale and many run in-house 340B pharmacies that price brand drugs far below retail. Our guide to free and sliding-scale clinics explains how to find one and what to bring to the appointment.
Rule out the cheaper upstream problem before you buy 12 months of pills. If the sleep complaint turns out to be sleep-disordered breathing rather than primary insomnia, the cost math changes entirely. Our guides to sleep study costs and CPAP machine costs cover what the diagnostic path runs for a cash payer, and oral appliance therapy covers the non-machine alternative.
Verify any quoted price before you pay it. Pharmacy cash quotes on brand-only drugs vary more than most people expect. Our fair price checker shows the current national range so you know whether the number you were given is out of line, and if a pharmacy or clinic bill is already in dispute, our negotiation script gives you the wording.
The Bottom Line
Belsomra is a roughly $475-a-month drug in cash terms and will stay there until a generic suvorexant actually launches, which tentative approval alone does not deliver and which the Orange Book suggests may not happen before 2029 at the earliest. The four strengths all cost the same, so there is no dose-shopping angle.
If you are uninsured, ignore the $30 coupon headline entirely. It is void for you by its own terms. Apply to the Merck Patient Assistance Program, call 800-727-5400 to confirm the current income criteria, and use a free discount card at the cheapest of three pharmacies while the application is pending. If you want to see how the newer drugs in the same class compare, our Quviviq cost guide prices daridorexant and Dayvigo side by side.